A

Acura Pharmaceuticals Inc
OTC:ACUR

Watchlist Manager
Acura Pharmaceuticals Inc
OTC:ACUR
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: $33.2k

Net Margin

-56.2%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-56.2%
=
Net Income
$-879k
/
Revenue
$1.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-56.2%
=
Net Income
$-879k
/
Revenue
$1.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Acura Pharmaceuticals Inc
OTC:ACUR
32.5k USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
96.4B EUR
Loading...

Market Distribution

Lower than 82% of companies in the United States of America
Percentile
18th
Based on 15 072 companies
18th percentile
-56.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Acura Pharmaceuticals Inc
Glance View

Market Cap
33.2k USD
Industry
Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. The company is headquartered in Palatine, Illinois. The company went IPO on 2000-09-12. The firm has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The firm's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The firm's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The firm's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.

ACUR Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-56.2%
=
Net Income
$-879k
/
Revenue
$1.6m
How has Net Margin changed over time?

Over the last 3 years, Acura Pharmaceuticals Inc’s Net Margin has increased from -937.1% to -56.2%. During this period, it reached a low of -2 094.8% on Jun 30, 2019 and a high of 1.4% on Jun 30, 2020.

Back to Top